These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date and reported results 2005-005187-90 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation alone in Patients with Aggressive B-cell lymphoma: NHL-13 2014-08-11 bad-data
Not reported 2006-001989-16 Phase II study of Oxaliplatin / Irinotecan / Cetuximab as first line therapy in locally advanced or metastatic gastric cancer 2009-11-01 due-trials
Reported results 2007-004970-24 Multizentrische Studie über die Cardiotoxizität von R-CHOP (Rituximab, Cyclophosphamid, Doxorubicin, Vincristin und Prednisolon) v. R-COMP (Rituximab, Cyclophosphamid, liposomalem Doxorubicin, Vincris... 2012-01-13 due-trials
Reported results Terminated 2008-000765-33 Phase II Study to Investigate the Treatment of Patients with NSCLC Stage IIIB and IV without the Option of Surgery with a Combination of Cisplatin, Docetaxel and Bevacizumab 2012-12-06 due-trials
Reported results 2008-000767-41 Phase II Trial of Rituximab Plus 2CdA in Patients with Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) 2011-09-30 due-trials
Reported results Terminated 2008-001016-21 Multizentrische Phase II Studie: Induktionschemotherapie und Chemoradiotherapie jeweils in Kombination mit Cetuximab bei Patienten mit nicht-metastasiertem Ösophaguskarzinom 2012-03-01 due-trials
Exempt, with results 2008-001430-27 Fludarabine/Rituximab combined with escalating doses of Lenalidomide followed by Rituximab/Lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with concomitant evaluati... 2012-01-16 not-yet-due
Reported results Terminated 2008-004530-25 Lapatinib plus Caelyx in patients with advanced metastatic breast cancer following failure of Trastuzumab therapy – a Phase II study 2012-05-22 due-trials
Exempt, with results 2008-004987-37 Bendamustine Combined with Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) – A Phase I/II Trial with Concomitant Evaluation of Safety and Efficacy 2012-08-06 not-yet-due
Ongoing 2008-006128-79 Phase II Study of Oxaliplatin / Irinotecan / Bevacizumab Followed by Docetaxel / Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients not-yet-due
Exempt, with results Terminated 2008-006919-20 Phase I/II Trial of Lenalidomide in Combination with Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients with Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL) 2012-10-22 not-yet-due
Completed, but no date, and reported results Terminated 2009-011337-27 A two-stage multicenter phase II trial of concurrent induction chemoimmunotherapy with epirubicine, oxaliplatin, capecitabine and panitumumab in KRAS wild-type, resectable type II gastric adenocarci... bad-data
Listed as ongoing, but also has a completion date and reported results 2009-013651-29 MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation alone in Patients with Chronic Lymphocytic Leukemia 2017-11-28 bad-data
Exempt, with results 2009-017147-33 A Phase I/II Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukemia 2016-02-08 not-yet-due
Reported results 2011-002921-23 Pharmacokinetics and metabolic activation of capecitabine when given concomitantly with oxaliplatin and the monoclonal antibody cetuximab 2014-03-27 due-trials
Ongoing 2011-003217-41 Biomarker directed treatment in metastatic colorectal cancer not-yet-due
Exempt, with results 2011-004912-43 Fludarabine/Rituximab combined with escalating doses of Lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with escalating starting dose of Lenalidomide and concomitan... 2015-01-15 not-yet-due
Ongoing 2011-005540-99 Randomised Phase II Pilot Studiy: Induction Chemotherapy with Docetaxel, Cisplatin und Cetuximab versus Docetaxel, Cisplatin und 5 FU followed by Radiotherapy with Cetuximab for locally advanced or n... not-yet-due
Reported results 2011-005818-10 PHASE II TRIAL OF RITUXIMAB (MABTHERA®) PLUS LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT) 2015-02-28 due-trials
Completed, report not yet due 2012-005593-64 Capecitabine in combination with Bendamustine in women with pretreated locally advanced or metastatic Her2-negative breast cancer, a Phase II Trial 2018-03-15 not-yet-due
Reported results Terminated 2013-001564-37 One arm, Open label, Interventional, non-comparative Study to assess Changes in Lipids and Lipoproteins in HIV infected Women with Hyperlipidemia after Switch from boosted Protease Inhibitors to Ralte... 2015-12-18 due-trials
Exempt 2013-003505-26 A “window of opportunity” trial with Brentuximab Vedotin and Imatinib in patients with relapsed or refractory ALK+ anaplastic large cell lymphoma or patients ineligible for chemotherapy not-yet-due
Ongoing 2014-002749-23 Ixazomib in combination to thalidomide - dexamethasone for patients with relapsed and/or refractory multiple myeloma not-yet-due
Ongoing 2014-003833-24 Randomized phase III study: Supplemental parenteral nutrition for patients with locally advanced inoperable tumors of the head and neck, receiving definitive radiotherapy with Cetuximab or Cisplatin not-yet-due
Ongoing 2016-000475-24 A randomized Phase II, 2-armed study in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM) comparing Carfilzomib + Thalidomide + dexamethasone (KTd) versus Carfilzomib + ... not-yet-due
Exempt 2016-001421-13 Ixazomib (MLN9708) in combination with carboplatin in pretreated women with advanced triple negative breast cancer (CARIXA) not-yet-due
Ongoing 2016-001760-10 Phase II single-arm “window-of-opportunity” study of a combination of obinutuzumab (GA-101) and venetoclax (ABT-199) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not-yet-due
Ongoing 2018-000924-32 Denosumab for high risk SMM and SLiM CRAB positive, early myeloma patients- a randomized, placebo controlled phase II trial “DEFENCE” (DEnosumab For the rEductioN of the smoldering myeloma transformat... not-yet-due